December 20, 2019 – 3D Medicines, Inc. (“3D Medicines”) announced that it has signed a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Alphamab”), a wholly owned subsidiary of Alphamab Oncology (Stock code: 9966.HK) and TRACON Pharmaceuticals (“TRACON”) for the clinical development and commercialization of KN035, a PD-L1 single-domain antibody, in soft tissue sarcoma in North America.

On September 19, 2019, 3D Medicines Inc. attended the 22nd annual meeting of Chinese Society of Clinical Oncology (CSCO). Toshio Shimizu, M.D., PhD. from National Cancer Center Hospital, gave an oral presentation on the Clinical Trial Periodic Report of the phase I study for Envafolimab (KN035), a subcutaneous anti-PD-L1 single domain antibody from 3D Medicines, in advanced solid tumor patients in Japan. Details of the presentation are listed as follows: